Bullous pemphigoid following the replacement of vildagliptin with anagliptin

J Dermatol. 2017 Oct;44(10):e238-e239. doi: 10.1111/1346-8138.13941. Epub 2017 Jul 7.

Authors

Kazumasa Oya¹, Masanao Fujii², Shijima Taguchi¹, Wataru Nishie³, Kentaro Izumi³, Hiroshi Shimizu³

Affiliations

¹ Division of Dermatology, Mito Kyodo General Hospital, Mito, Japan.
² Department of Diabetes and Endocrinology, Mito Kyodo General Hospital, Mito, Japan.
³ Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

PMID: 28688147
DOI: 10.1111/1346-8138.13941

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Cutaneous
Aged, 80 and over
Betamethasone / analogs & derivatives
Betamethasone / therapeutic use
Blood Glucose / analysis
Blood Glucose / drug effects
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Drug Substitution / adverse effects
Glucocorticoids / therapeutic use
Humans
Male
Pemphigoid, Bullous / chemically induced*
Pemphigoid, Bullous / diagnosis
Pemphigoid, Bullous / drug therapy
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Treatment Outcome
Vildagliptin / administration & dosage*

Substances

Blood Glucose
Dipeptidyl-Peptidase IV Inhibitors
Glucocorticoids
Pyrimidines
Betamethasone
Vildagliptin
anagliptin
diflorasone